RT @ascanet: Poos et al. integrated whole-genome seq, scRNA seq, and scATAC seq together with mitochondrial DNA mutations to define subclon…
RT @ascanet: Poos et al. integrated whole-genome seq, scRNA seq, and scATAC seq together with mitochondrial DNA mutations to define subclon…
RT @ascanet: Poos et al. integrated whole-genome seq, scRNA seq, and scATAC seq together with mitochondrial DNA mutations to define subclon…
RT @ascanet: Poos et al. integrated whole-genome seq, scRNA seq, and scATAC seq together with mitochondrial DNA mutations to define subclon…
Poos et al. integrated whole-genome seq, scRNA seq, and scATAC seq together with mitochondrial DNA mutations to define subclonal architecture and evolution for longitudinal samples from patients with relapsed or refractory multiple myeloma. ➡️ https://t.co
RT @KarstenRippe: Glad to see that the joint study of our team from @HDMyeloma and @DKFZ on how tumor heterogeneity drives therapy resistan…
and here is the link for the free download of the paper: https://t.co/3wrWeY9fec
RT @KarstenRippe: Glad to see that the joint study of our team from @HDMyeloma and @DKFZ on how tumor heterogeneity drives therapy resistan…
RT @KarstenRippe: Glad to see that the joint study of our team from @HDMyeloma and @DKFZ on how tumor heterogeneity drives therapy resistan…
RT @KarstenRippe: Glad to see that the joint study of our team from @HDMyeloma and @DKFZ on how tumor heterogeneity drives therapy resistan…
RT @KarstenRippe: Glad to see that the joint study of our team from @HDMyeloma and @DKFZ on how tumor heterogeneity drives therapy resistan…
Glad to see that the joint study of our team from @HDMyeloma and @DKFZ on how tumor heterogeneity drives therapy resistance in multiple #myeloma is now out in Blood https://t.co/tbNpd0l7X6 and highlighted by @uniklinik_hd https://t.co/SLvOe2YojM https://t.
RT @HDMyeloma: Have a look at our recent work @BloodJournal that points towards multi-factorial resistance mechanisms and new options for c…
RT @HDMyeloma: Have a look at our recent work @BloodJournal that points towards multi-factorial resistance mechanisms and new options for c…
RT @HDMyeloma: Have a look at our recent work @BloodJournal that points towards multi-factorial resistance mechanisms and new options for c…
ฅNya! Here's the latest 🗞 from [ Blood ]: " Resolving therapy resistance mechanisms in multiple myeloma by multi-omics subclone analysis" 🔗: https://t.co/U2vpbQ5O5E
RT @HDMyeloma: Have a look at our recent work @BloodJournal that points towards multi-factorial resistance mechanisms and new options for c…
RT @HDMyeloma: Have a look at our recent work @BloodJournal that points towards multi-factorial resistance mechanisms and new options for c…
RT @HDMyeloma: Have a look at our recent work @BloodJournal that points towards multi-factorial resistance mechanisms and new options for c…
RT @HDMyeloma: Have a look at our recent work @BloodJournal that points towards multi-factorial resistance mechanisms and new options for c…
RT @KarstenRippe: The analysis of subclone-resolved therapy resistance in multiple #myeloma @BloodJournal by a multiomics approach reveals…
Have a look at our recent work @BloodJournal that points towards multi-factorial resistance mechanisms and new options for common treatment vulnerabilities of individual tumor subclones in #mmsm https://t.co/qHXfoSN3Kc. https://t.co/IbOzR8KJCx
RT @KarstenRippe: The analysis of subclone-resolved therapy resistance in multiple #myeloma @BloodJournal by a multiomics approach reveals…
RT @KarstenRippe: The analysis of subclone-resolved therapy resistance in multiple #myeloma @BloodJournal by a multiomics approach reveals…
RT @KarstenRippe: The analysis of subclone-resolved therapy resistance in multiple #myeloma @BloodJournal by a multiomics approach reveals…
Resolving therapy resistance mechanisms in multiple myeloma by multi-omics subclone analysis https://t.co/msgjtW7b5g https://t.co/lgJf2vI4iR
RT @KarstenRippe: The analysis of subclone-resolved therapy resistance in multiple #myeloma @BloodJournal by a multiomics approach reveals…
RT @KarstenRippe: The analysis of subclone-resolved therapy resistance in multiple #myeloma @BloodJournal by a multiomics approach reveals…
RT @KarstenRippe: The analysis of subclone-resolved therapy resistance in multiple #myeloma @BloodJournal by a multiomics approach reveals…
RT @KarstenRippe: The analysis of subclone-resolved therapy resistance in multiple #myeloma @BloodJournal by a multiomics approach reveals…
The analysis of subclone-resolved therapy resistance in multiple #myeloma @BloodJournal by a multiomics approach reveals different mechanisms that can occur in parallel https://t.co/tbNpd0l7X6. Kudos to everyone involved for pushing this one across the fin
Resolving therapy resistance mechanisms in multiple myeloma by multi-omics subclone analysis https://t.co/8tXCsoKBoK
Resolving therapy resistance mechanisms in multiple myeloma by multi-omics subclone analysis https://t.co/aZ4w1HkvxM
Resolving therapy resistance mechanisms in multiple myeloma by multi-omics subclone analysis https://t.co/4qcvG6DSRE